CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.

MENU
Image of a Man
Fastest SCIG
infusion rates and
fewest needlesticks.1
Fastest SCIG
infusion rates
and fewest
needlesticks.1

CUSTOMIZED ADMINISTRATION

CUVITRU can offer your patients an optimized treatment experience1

Whether your patients prefer infusions that take less than an hour or fewer needlesticks, CUVITRU [Immune Globulin Subcutaneous (Human)] 20% Solution is the SCIG of choice with administration that can be customized to meet their individual needs.1,2

Fastest SCIG infusion rates1

The median duration of once-weekly infusions was <1 hour (0.95 hours; range: 0.2-6.4 hours) in the North American clinical study.

  • Approximately 94% of infusions were completed within 2 hours3
  • Infuse at rates up to 60 mL/h/site in up to 4 sites simultaneously for a maximum total of 240 mL/h
  • For patients looking to minimize infusion time, CUVITRU may allow delivery of a full week’s dose in <15 min—with even shorter durations possible with more frequent dosing*
Fewest needlesticks1

84.9% of infusions (N=4314) were administered using only 1 or 2 infusion sites (18.5%=1 site; 66.4%=2 sites) in the North American clinical study.

  • Infuse weekly in <1 hour in 1-2 sites
  • Patients can infuse up to 60 mL/site, and use up to 4 sites simultaneously
  • The use of more infusion sites may be beneficial for patients who want to reduce the volume administered per site or overall infusion duration
Infuse from daily to every 2 weeks1,2

Patients who had received IVIG previously reported that CUVITRU fit better into their schedules and was more convenient than IVIG infusion.†

  • With the highest infusion volume (60 mL/h/site, as tolerated) compared with any other conventional SCIG option, a weekly or biweekly infusion schedule is possible for your patients.

*If a patient is 75 kg (165 lbs) and was prescribed 36 g of IVIG per month, you could switch your patient to 12 g of CUVITRU weekly. After the first 2 infusions, subsequent infusions of CUVITRU could be completed in 15 mins at a rate of 60 mL/h/site using 4 sites simultaneously.

†CUVITRU was shown to significantly improve patient quality of life in terms of Convenience (TSQM-9 difference 11.11; P<0.001) and Treatment Interference (LQI difference 1.50; P=0.008) when compared to IVIG treatment.

See how CUVITRU is administered.

Watch the video to learn more about CUVITRU administration.

View examples of 3 patients' infusion sites

Infusion experience

View examples of 3 patients’ infusion sites from pre-infusion to 48 hours after.

Volume infused per physician guidance based on patient’s specific clinical condition. It may be different for other patients.

Patient No. 1
Male, age 59

  • 60 mL infusion in 1 site of the abdomen
  • Infused at maximum rate of 60 mL/h/site

Patient No. 2
Male, age 16

  • 60 mL infusion in 1 site of the thigh
  • Infused at maximum rate of 60 mL/h/site

Patient No. 3
Female, age 14

  • 40 mL infusion in 1 site of the thigh
  • Infused at rate of 40 mL/h/site

Explore administration parameter combinations based on needlesticks and infusion frequency, plus learn about the proper ancillary supplies.

Infusion Calculator & Ancillary Supplies
  1. CUVITRU [Prescribing Information]. Lexington, MA: Baxalta US Inc.
  2. Suez D, Stein M, Gupta S, et al. Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with
    primary immunodeficiency diseases in North America. J Clin Immunol. 2016;36(7):700-712.
  3. Data on file. Takeda US Inc. 2015.